Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$3.22
-0.14 (-4.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-293.8M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
32.2x
↑EV/EBITDA
7.0x
↓ROE
-9.8%
↓Gross Margin
59.8%
↑Debt/Equity
-5.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+91.9%
FCF CAGR
—
FCF margin
-25.0%
FCF / Net income
-5.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $586.3M · net income $27.9M · FCF $-146.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $586.3M | $586.3M | $489.7M | $91.4M | $83.0M |
| Net Income | $27.9M | $27.9M | $-231.9M | $-551.7M | $-513.6M |
| EBITDA | $311.1M | $311.1M | $-32.3M | $-493.7M | $-453.8M |
| EPS | 0.10 | 0.10 | -0.87 | -2.43 | -2.60 |
| Gross Margin | 59.8% | 59.8% | 62.2% | -75.9% | 22.8% |
| Operating Margin | 13.3% | 13.3% | 14.2% | -388.1% | -417.3% |
| Net Margin | 4.8% | 4.8% | -47.3% | -603.4% | -618.6% |
| Balance Sheet | |||||
| Debt/Equity | -5.09 | -5.09 | -2.88 | -1.15 | -1.43 |
| Current Ratio | 1.75 | 1.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-146.3M | $-146.3M | $-293.8M | $-358.7M | $-361.4M |
| Returns | |||||
| ROE | -9.8% | -9.8% | 56.2% | 59.2% | 91.0% |
| Valuation | |||||
| P/E | 32.20 | 32.20 | — | — | — |
| EV/EBITDA | 6.99 | 6.99 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 19.7% | 19.7% | 435.6% | 10.1% | — |
| EPS Growth | 111.5% | 111.5% | 64.2% | 6.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.9%
EPS terminal req.
$0.29
Spread vs growth
69.6%
5Y implied EPS CAGR
28.2%
EPS terminal req.
$0.35
Spread vs growth
83.3%
10Y implied EPS CAGR
18.7%
EPS terminal req.
$0.56
Spread vs growth
92.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-71.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.87 → 0.10
Residual
-71.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.